Cell Source, Inc. (CLCS)

OTCMKTS · Delayed Price · Currency is USD
0.990
+0.140 (16.47%)
Mar 5, 2026, 9:30 AM EST
236.73%
Market Cap 48.33M
Revenue (ttm) n/a
Net Income (ttm) -6.57M
Shares Out 48.82M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 200
Average Volume 7,508
Open 0.990
Previous Close 0.850
Day's Range 0.990 - 0.990
52-Week Range 0.182 - 2.250
Beta -216.39
RSI 63.90
Earnings Date Mar 20, 2026

About Cell Source

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disea... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Itamar Shimrat
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol CLCS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.